| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Athira Pharma, Inc. | General Counsel and CCO | Common Stock | 112K | $32.8K | $0.29 | Jul 1, 2025 | Direct |
| Athira Pharma, Inc. | General Counsel and CCO | Restricted Stock Units | 36.7K | $32.2K | $0.56 | Jun 30, 2025 | Direct |
| Athira Pharma, Inc. | General Counsel and CCO | Stock Option (Right to Buy) | 85.9K | Mar 3, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ATHA | Athira Pharma, Inc. | Jun 30, 2025 | 3 | -$2.5K | 4 | Jul 2, 2025 | General Counsel and CCO |
| ATHA | Athira Pharma, Inc. | Mar 3, 2025 | 2 | $0 | 4 | Mar 4, 2025 | General Counsel and CCO |
| ATHA | Athira Pharma, Inc. | Dec 31, 2024 | 4 | -$2.77K | 4 | Jan 3, 2025 | General Counsel and CCO |
| ATHA | Athira Pharma, Inc. | Oct 1, 2024 | 2 | $0 | 4 | Oct 3, 2024 | General Counsel and CCO |
| ATHA | Athira Pharma, Inc. | Sep 3, 2024 | 3 | $12K | 4 | Sep 5, 2024 | GENERAL COUNSEL |
| ATHA | Athira Pharma, Inc. | Feb 14, 2024 | 1 | $0 | 4 | Feb 16, 2024 | GENERAL COUNSEL |
| ATHA | Athira Pharma, Inc. | Jan 4, 2024 | 3 | $11.7K | 4/A | Feb 16, 2024 | GENERAL COUNSEL |
| ATHA | Athira Pharma, Inc. | Jan 4, 2024 | 3 | $11.7K | 4 | Jan 8, 2024 | General Counsel |
| ATHA | Athira Pharma, Inc. | Jan 19, 2023 | 1 | $0 | 4 | Jan 23, 2023 | General Counsel |
| ATHA | Athira Pharma, Inc. | Jun 22, 2022 | 3 | $16.9K | 4 | Jun 24, 2022 | General Counsel |
| ATHA | Athira Pharma, Inc. | Jan 18, 2022 | 1 | $0 | 4 | Jan 20, 2022 | General Counsel |
| ATHA | Athira Pharma, Inc. | Nov 3, 2021 | 1 | $0 | 4 | Nov 5, 2021 | General Counsel |
| ATHA | Athira Pharma, Inc. | Jun 1, 2021 | 0 | $0 | 3 | Jun 1, 2021 | General Counsel |